High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy
Authors:
- Ravindra K. GuptaRGRavindra K. Gupta
- Ruth L. GoodallRGRuth L. Goodall
- Charles F. GilksCGCharles F. Gilks
- for the DART Virology Group and Trial TeamFTfor the DART Virology Group and Trial Team
- H. GrosskurthHGH. Grosskurth
Open Access
- 18 December 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 58 (7) , 1023-1026
Abstract
In a randomized comparison of nevirapine or abacavir with zidovudine plus lamivudine, routine viral load monitoring was not performed, yet 27% of individuals with viral failure at week 48 experienced resuppression by week 96 without switching. This supports World Health Organization recommendations that suspected viral failure should trigger adherence counseling and repeat measurement before a treatment switch is considered.Keywords
This publication has 16 references indexed in Scilit:
- Virological outcome and patterns of HIV‐1 drug resistance in patients with 36 months’ antiretroviral therapy experience in CameroonJournal of the International AIDS Society, 2013
- Residual Activity of Two HIV Antiretroviral Regimens Prescribed without Virological MonitoringAntimicrobial Agents and Chemotherapy, 2011
- Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48‐week randomized comparison with abacavir/zidovudine/lamivudine in HIV‐infected Ugandan adults with low CD4 cell countsHIV Medicine, 2010
- Viral Rebound and Emergence of Drug Resistance in the Absence of Viral Load Testing: A Randomized Comparison between Zidovudine‐Lamivudine plus Nevirapine and Zidovudine‐Lamivudine plus AbacavirThe Journal of Infectious Diseases, 2010
- Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trialThe Lancet, 2010
- Viremia, Resuppression, and Time to Resistance in Human Immunodeficiency Virus (HIV) Subtype C during First‐Line Antiretroviral Therapy in South AfricaClinical Infectious Diseases, 2009
- The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapyAIDS, 2009
- Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort studyThe Lancet, 2008
- Options for a Second-Line Antiretroviral Regimen for HIV Type 1-Infected Patients Whose Initial Regimen of a Fixed-Dose Combination of Stavudine, Lamivudine, and Nevirapine FailsClinical Infectious Diseases, 2007
- Virological and immunological impact of non-nucleoside reverse transcriptase inhibitor withdrawal in HIV-infected patients with multiple treatment failuresAIDS, 2004